Elsevier Preclinical Research in Down Syndrome: Insights for Pathophysiology and Treatments (Volume 251) (Progress in Brain Research, Volume 251)

Preclinical Research in Down Syndrome: From Bench to Bedside, Volume 251, the latest release in the Progress in Brain Research series, highlights new advances in the field. Chapters in this updated release include Exploring genetic and epigenetic mechanisms underlying cognitive deficits in Dow syndrome, The trisomy paradox: gene expression dysregulation domains, the Influence of allelic differences in mouse models of Down syndrome, Modelling Down syndrome in cells: From stem cells to organoids, Modelling Down syndrome in animals from the early stage to the new generation of models, Mapping behavioral landscapes in Down syndrome animal models, and more. Review "It is important to recognize that trisomy 21 does not receive enough attention from the scientific community. This is a unique book that brings to the medical community the vast work still needed to understand trisomy 21 and to improve outcomes of individuals with Down syndrome. The Trisomy 21 Research Society has done an excellent job supporting this publication and Mara Dierssen has achieved her goals well in editing this extremely important contribution." --Doody Review Provides a comprehensive view of new research in the field of Down Syndrome and its future roadmap About the Author Mara Dierssen is a Doctor in Medicine and Surgery from the University of Cantabria, (1989). She leads the Cellular and Systems Neurobiology laboratory at the Genomic Regulation Center (CRG) and is associate researcher of the Hospital del Mar Research Institute, where she promoted the creation of a translational research program to study new therapeutic approaches in intellectual disability. Her main current scientific interests are focused on the study of the neurobiological mechanisms underlying memory and learning and their alteration in complex diseases (polygenic and multifactorial) and in the development and application of this knowledge to the field of clinical practice. Among her scientific contributions in the field of neurobiology and neuropharmacology is the identification of the alterations of neuroplasticity in various intellectual deficiencies and psychiatric pathology, and the determination of their molecular mechanisms. She is internationally recognized in the study of Down syndrome, whose findings, especially the involvement of the DYRK1A gene in the neuronal pathology of this syndrome, have had a direct impact on the identification of new pharmacological targets. Dr. Dierssen has demonstrated for the first time significant beneficial effects of a pharmacological treatment that improves neuroplasticity in the field of intellectual disability, a finding that has revolutionized the therapeutic approaches in cognitive disorders. Her scientific interest in innovating tools and strategies, incorporating brain-computer interface technologies to improve communication in patients with cerebral palsy, or cognitive stimulation videogames are also in the forefront of Neuroscience. He has published more than 160 research papers in indexed scientific journals. At present, the H index (Hirsch Factor) of Dr. Dierssen is 46. Dr. Dierssen is one of the few Spanish members of the Europaea Academy of Sciences, and has held different positions of responsibility, being president of the Spanish Society of Neurosciences, the International Behavioral and Neural Genetics Society and the Trisomy 21 Research Society. She has obtained the Ramón Trías Fargas Prizes, National Prize of Thought and Scientific Culture of the Generalitat of Catalonia, Jaime Blanco, Sisley-Lejeune Award, Hillie-Mahoney Award, Trébol Down Spain Award, Optimists Committed Award, Trifermed Social Impact of Healthcare Award, BigVang Medal among others. She has been named Distinguished Student of the University of Cantabria, and is an honorary member of the College of Physicians. She is elected member of the European Allianz for the Brain (EDAB), founding member o